Higher therapeutic CsA levels early post transplantation reduce risk of acute GVHD and improves survival

Bone Marrow Transplantation

Volumn 49, Issue 1, 2014, Pages 122-125

  Rogosheske, J R ^a   Fargen, A D ^a   Defor, T E ^a   Warlick, E ^a   Arora, M ^a   Blazar, B R ^a   Weisdorf, D J ^a   Brunstein, C G ^a  

^a Department of Medicine ^*  (United States)

Author keywords

Allogeneic transplantation; Calcineurin inhibitor; CsA; GVHD

Indexed keywords

CYCLOSPORIN A;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE ASSOCIATION; DONOR; DRUG BLOOD LEVEL; DRUG MONITORING; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; RISK REDUCTION; SIBLING; SURVIVAL;

ADOLESCENT; ADULT; ALLELES; CALCINEURIN; CORD BLOOD STEM CELL TRANSPLANTATION; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SIBLINGS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891839554     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.139     Document Type: Article

References (18)

1. Billingham RE, Brent L. A simple method for inducing tolerance of skin homografts in mice. Transplant Bull 1957; 4: 67-71.
2. Yee GC, Self SG, McGuire TR, Carlin J, Sanders JE, Deeg HJ. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med 1988; 319: 65-70.
3. Lamparelli T, Van Lint MT, Gualandi F, Occhini D, Barbanti M, Sacchi N et al. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience. Bone Marrow Transplant 1997; 20: 1057-1062.
4. Kedmi M, Dray L, Grisariu S, Resnick IB, Stepensky P, Aker M et al. The effect of cyclosporine initiation time on the outcome of matched allogeneic stem-cell transplantation following fludarabine-based conditioning. Transpl Int 2012; 25: 1241-1247.
5. Ram R, Storer B, Mielcarek M, Sandmaier BM, Maloney DG, Martin PJ et al. Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 414-422.
6. Malard F, Szydlo RM, Brissot E, Chevallier P, Guillaume T, Delaunay J et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versushost disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 28-34.
7. Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007; 110: 3064-3070.
8. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105: 1343-1347.
9. Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, Defor TE, Gooley TA et al. Allogeneic hematopoietic cell transplantation for hematological malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010; 116: 4693-4699.
10. Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood 2012; 119: 4083-4090.
11. Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997; 53: 1005-1037.
12. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
13. Cox DR. Regression models and life tables. J Royal Stat Soc B. 1972; 34: 187-220.
14. Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika 1981; 68: 373-379.
15. Tarone RE, Ware J. Tests for trend in life table analysis. Biometrika 1975; 62: 679-687.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
17. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012; 12: 443-458.
18. MacMillan ML, Weisdorf DJ, Brunstein CG, Cao Q, DeFor TE, Verneris MR et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood 2009; 113: 2410-2415.